Plus Therapeutics says CNSide cost-of-care analysis shows up to 40% reduction in leptomeningeal metastases healthcare costs

PLUS THERAPEUTICS INC

PSTV

0.00

Plus Therapeutics disclosed a health-economics study on its CNSide cerebrospinal fluid assay for leptomeningeal metastases, with results already presented at ISPOR 2026.
The analysis found earlier detection supported by CNSide can materially lower overall care costs by enabling earlier treatment decisions.
Estimated savings were about 40%, driven by fewer hospital stays and more targeted use of LM-directed care.
The work was co-authored with Harvard T.H. Chan School of Public Health, supporting the assay’s US commercialization and payer discussions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260730PRIMZONEFULLFEED9725541) on May 26, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.